Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J COVID-19 Vaccine Rollout Resumes In EU With New Rare Blood Clot Warning

Countries May Impose Age Restrictions

Executive Summary

Similarities to AstraZeneca blood clots are clear, but more research needed before any ‘class effect’ conclusions can be drawn.

You may also be interested in...



COVID-19 Vaccine Updates: VITT Has High Mortality, Myocarditis Is Benign Short-Term

Recipients of AstraZeneca’s vaccine hospitalized with vaccine-induced immune thrombocytopenia and thrombosis (VITT) had overall mortality of 22%, NEJM study finds. JAMA reports 15 children who had myocarditis following Pfizer/BioNTech vaccine were mildly affected. Efficacy of Moderna vaccine in adolescents and durability of Pfizer vaccine in cancer treatment recipients is also reported.

J&J, Hopeful On COVID-19 Vaccine Outlook, Looks To Restore Public Confidence

The company recorded $100m in revenues from the vaccine in the first quarter, before administration was paused in the US and Europe to review a rare risk of blood clots.

Emergent Suspends COVID-19 Vaccine API Manufacturing As US FDA Inspects Bayview Plant

After discovery of viral vector cross-contamination, AstraZeneca quit, J&J took control and the FDA launched inspection.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144222

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel